by Uma Balasubramanian, Peter Salmon, David Robinson, and Jinyou Zhang, PhD
Volume 5, Issue 2 (Summer 2006)
Since the mid-1970’s, when Kohler and Milstein first discovered the process by which myeloma cells and splenocytes could be fused to produce monoclonal antibodies (MAbs), a whole new world of important therapeutic, prophylactic and diagnostic products has opened up, bringing in huge benefits for patients and manufacturers. The total sales of therapeutic MAbs reached more than $13 billion in 2005. Sixteen of the 18 FDA-approved MAbs came to the market after 1997, and over 150 are currently in clinical development, suggesting their increasing medical importance and the remarkable, recent advancements in development technology…
Citation:
Balasubramanian U, Salmon P, Robinson D, Zhang J. Characterization and Release of Raw Materials Used in Upstream Processes for Production of Monoclonal Antibodies by Mammalian Cell Culture. BioProcess J, 2006; 5(2): 7-13. https://doi.org/10.12665/J52.Balasubramanian